Jane Street’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-50,114
| Closed | -$1.08M | – | 11497 |
|
|
2025
Q4 | $1.26M | Sell |
50,114
-243,085
| -83% | -$5.7M | ﹤0.01% | 5678 |
|
|
2025
Q3 | $6.64M | Buy |
293,199
+47,000
| +19% | +$1.1M | ﹤0.01% | 2987 |
|
|
2025
Q2 | $4.26M | Sell |
246,199
-9,893
| -4% | -$183K | ﹤0.01% | 3228 |
|
|
2025
Q1 | $5.6M | Buy |
256,092
+160,107
| +167% | +$4.42M | ﹤0.01% | 2769 |
|
|
2024
Q4 | $3.06M | Buy |
95,985
+76,705
| +398% | +$2.31M | ﹤0.01% | 3405 |
|
|
2024
Q3 | $556K | Sell |
19,280
-181,609
| -90% | -$6.73M | ﹤0.01% | 7004 |
|
|
2024
Q2 | $7.71M | Buy |
200,889
+71,880
| +56% | +$3.26M | ﹤0.01% | 2342 |
|
|
2024
Q1 | $7.58M | Sell |
129,009
-305,692
| -70% | -$19.5M | ﹤0.01% | 2096 |
|
|
2023
Q4 | $26M | Buy |
434,701
+161,475
| +59% | +$8.19M | 0.01% | 1064 |
|
|
2023
Q3 | $10.4M | Sell |
273,226
-207,856
| -43% | -$9.13M | ﹤0.01% | 1729 |
|
|
2023
Q2 | $43.8M | Buy |
481,082
+417,698
| +659% | +$36M | 0.01% | 664 |
|
|
2023
Q1 | $4.18M | Buy |
63,384
+49,363
| +352% | +$2.85M | ﹤0.01% | 2695 |
|
|
2022
Q4 | $725K | Sell |
14,021
-2,977
| -18% | -$158K | ﹤0.01% | 5524 |
|
|
2022
Q3 | $1.16M | Sell |
16,998
-77,584
| -82% | -$4.59M | ﹤0.01% | 5149 |
|
|
2022
Q2 | $4.28M | Buy |
94,582
+19,472
| +26% | +$888K | ﹤0.01% | 2897 |
|
|
2022
Q1 | $3.82M | Sell |
75,110
-25,601
| -25% | -$1.13M | ﹤0.01% | 3497 |
|
|
2021
Q4 | $4.76M | Buy |
100,711
+84,768
| +532% | +$3.34M | ﹤0.01% | 2932 |
|
|
2021
Q3 | $525K | Sell |
15,943
-18,619
| -54% | -$1.05M | ﹤0.01% | 7188 |
|
|
2021
Q2 | $2.18M | Buy |
34,562
+11,464
| +50% | +$592K | ﹤0.01% | 4170 |
|
|
2021
Q1 | $991K | Sell |
23,098
-33,854
| -59% | -$1.6M | ﹤0.01% | 5473 |
|
|
2020
Q4 | $3.26M | Buy |
56,952
+14,382
| +34% | +$608K | ﹤0.01% | 2714 |
|
|
2020
Q3 | $1.28M | Buy |
42,570
+19,591
| +85% | +$585K | ﹤0.01% | 3684 |
|
|
2020
Q2 | $750K | Buy |
+22,979
| New | +$738K | ﹤0.01% | 4490 |
|
|
2020
Q1 | – | Sell |
-8,135
| Closed | -$249K | – | 5259 |
|
|
2019
Q4 | $249K | Sell |
8,135
-87,589
| -92% | -$2.42M | ﹤0.01% | 4504 |
|
|
2019
Q3 | $2.31M | Buy |
95,724
+82,285
| +612% | +$2.26M | ﹤0.01% | 1657 |
|
|
2019
Q2 | $341K | Buy |
+13,439
| New | +$273K | ﹤0.01% | 4046 |
|
Other funds holding APLS
Jane Street's APLS Position: Q1 2026 in Review
Jane Street sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 50,114 shares — an estimated $1.08M sold.
Jane Street first reported a position in APLS in Q2 2019 and held it in 26 quarters. The position peaked at $43.8M in Q2 2023. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.
- Jane Street reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Jane Street sold 50,114 Apellis Pharmaceuticals shares in Q1 2026, an estimated $1.08M.
- Jane Street first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 26 quarters.
- Jane Street's Apellis Pharmaceuticals position peaked at $43.8M in Q2 2023.
- 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.